ReviewFrontiers in immunology2022
Exosomes: A potential tool for immunotherapy of ovarian cancer.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 82 citations in OpenAlex.
- Current Advances of Molecular Biomarkers and Liquid Biopsies Techniques in Ovarian Cancer.Cancer medicine · 2026Review
- Potential Role of Exosomes in the Pathogenesis, Diagnosis, and Treatment of Ovarian Cancer.Cancers · 2026Review
- Exosomes in oncofertility: emerging roles in chemotherapy-induced reproductive damage and fertility preservation.Reproduction & fertility · 2026Review
- DUSP5 contributes to platinum resistance in ovarian cancer: single-cell discovery and functional validation.Frontiers in pharmacology · 2026Article
- Advances in the use of exosomes for the diagnosis and treatment of ovarian cancer.World journal of surgical oncology · 2025Review
- Knowledge, attitudes, and barriers regarding health promotion of ovarian cancer among community pharmacists in Jordan.Future science OA · 2025Article
- Trophoblast cell surface antigen 2 (TROP2) from ascitic extracellular vesicles drives peritoneal metastasis of ovarian cancer by mesothelial-to-mesenchymal transition.Journal of ovarian research · 2025Article
- Patient-derived extracellular matrix from decellularized high-grade serous ovarian carcinoma tissues as a biocompatible support for organoid growth.Translational oncology · 2025Article
- Applications of Nanoparticles in the Diagnosis and Treatment of Ovarian Cancer.Nanomaterials (Basel, Switzerland) · 2025Review
- Clinical characteristics and predictors of survival in 284 patients with recurrent epithelial ovarian cancer: a large-scale retrospective analysis.Annals of medicine and surgery (2012) · 2025Article
- Review
- Development and validation of a nomogram model of lung metastasis in breast cancer based on machine learning algorithm and cytokines.BMC cancer · 2025Article
- Downregulated STAT3 and STAT5B are prognostic biomarkers for colorectal cancer and are associated with immune infiltration.Discover oncology · 2025Article
- Exosomal ncRNAs in reproductive cancers†.Biology of reproduction · 2025Review
- Roles and functions of tumor-infiltrating lymphocytes and tertiary lymphoid structures in gastric cancer progression.Frontiers in immunology · 2025Review
- Immunosuppressive tumor microenvironment in pancreatic cancer: mechanisms and therapeutic targets.Frontiers in immunology · 2025Review
- Immunotherapeutic strategies for invasive bladder cancer: a comprehensive review.Frontiers in immunology · 2025Review
- Metabolic reprogramming and immune microenvironment characteristics in laryngeal carcinoma: advances in immunotherapy.Frontiers in immunology · 2025Review
- The role of Treg cells in colorectal cancer and the immunotherapy targeting Treg cells.Frontiers in immunology · 2025Review
- The role of tumor-associated macrophages in HPV induced cervical cancer.Frontiers in immunology · 2025Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is a malignant tumor of the female reproductive system, with a very poor prognosis and high mortality rates. Chemotherapy and radiotherapy are the most common treatments for ovarian cancer, with unsatisfactory results. Exosomes are a subpopulation of extracellular vesicles, which have a diameter of approximately 30-100 nm and are secreted by many different types of cells in various body fluids. Exosomes are highly stable and are effective carriers of immunotherapeutic drugs. Recent studies have shown that exosomes are involved in various cellular responses in the tumor microenvironment, influencing the development and therapeutic efficacy of ovarian cancer, and exhibiting dual roles in inhibiting and promoting tumor development. Exosomes also contain a variety of genes related to ovarian cancer immunotherapy that could be potential biomarkers for ovarian cancer diagnosis and prognosis. Undoubtedly, exosomes have great therapeutic potential in the field of ovarian cancer immunotherapy. However, translation of this idea to the clinic has not occurred. Therefore, it is important to understand how exosomes could be used in ovarian cancer immunotherapy to regulate tumor progression. In this review, we summarize the biomarkers of exosomes in different body fluids related to immunotherapy in ovarian cancer and the potential mechanisms by which exosomes influence immunotherapeutic response. We also discuss the prospects for clinical application of exosome-based immunotherapy in ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.